New York, USA, July 07, 2025 (GLOBE NEWSWIRE) — Bispecific Antibody Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight<\/b><\/p>\n
The bispecific antibody market is experiencing rapid growth, primarily driven by the increasing prevalence of complex chronic diseases, such as cancer and autoimmune disorders, for which conventional therapies often fall short. These innovative molecules offer dual-targeting capabilities, enabling superior efficacy and therapeutic precision. Ongoing R&D advancements and increasing regulatory approvals are driving the clinical adoption of these technologies.<\/i><\/b><\/p>\n
DelveInsight\u2019s ‘<\/b>Bispecific Antibody Competitive Landscape \u2013 2025<\/b><\/a>‘<\/b> report provides comprehensive global coverage of available, marketed, and pipeline bispecific antibodies in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space and future growth potential of the bispecific antibody competitive domain.<\/p>\n Key Takeaways from the Bispecific Antibody Pipeline Report<\/b><\/p>\n Request a sample and discover the recent advances in the bispecific antibody market @ Bispecific Antibody Competitive Landscape Report<\/b><\/a><\/p>\n Bispecific Antibody Overview<\/b><\/p>\n Bispecific antibodies (bsAbs) are engineered molecules that simultaneously bind two different antigens. One binding site typically targets the CD3 receptor on cytotoxic T lymphocytes, thereby activating them, while the other site is directed toward tumor-associated antigens such as CD19, CD20, CD33, CD123, HER2, EpCAM, BCMA, CEA, and others. This dual targeting brings T cells into close proximity with tumor cells, leading to T cell activation and tumor cell destruction.<\/p>\n Beyond cancer treatment, bispecific antibodies have been developed for various other diseases. For instance, in osteoporosis, a bispecific antibody targets and inhibits sclerostin and Dkk1, both negative regulators of the Wnt signaling pathway, thereby promoting osteoblast activity and bone growth. Another example is ACE910 (emicizumab), which bridges coagulation factors IX and X to restore hemostasis in patients with hemophilia A by enhancing the coagulation cascade. A different bispecific antibody under investigation for Alzheimer\u2019s disease targets both the transferrin receptor (facilitating blood\u2013brain barrier transport) and BACE1, an enzyme involved in amyloid-beta production.<\/p>\n Bispecific antibodies often target cytokines such as TNF, IL1, IL4, IL14, IL17, IL23, and others in autoimmune diseases. Using two separate monoclonal antibodies (mAbs) against cytokines has been associated with increased side effects without added efficacy. Bispecific antibodies, however, can combine two anti-cytokine specificities in a single molecule, potentially offering greater therapeutic benefits. For example, IL17, IL23, IL6, and TNF are key targets in psoriasis. ABT122, which targets both TNF\u03b1 and IL17A, has shown clinical benefit in rheumatoid and psoriatic arthritis. In contrast, COVA322, which has the same targets, was discontinued in early clinical trials due to safety issues. ABT981, targeting IL1\u03b1 and IL1\u03b2, is aimed at treating osteoarthritis by neutralizing inflammatory cytokines found in joint tissues.<\/p>\n Bispecific antibodies offer notable advantages over traditional monospecific antibodies. They can more effectively guide immune effector cells to tumors, increasing cytotoxic responses. Their ability to bind two distinct antigens provides greater target specificity and may enhance therapeutic efficacy. Compared to using a combination of two separate monoclonal antibodies, bispecifics can reduce development and clinical costs. Moreover, since some disease-driving molecules act through multiple pathways and many tumors express multiple growth-promoting receptors, dual targeting on the same cell may boost antiproliferative effects and help prevent resistance.<\/p>\n Approved Bispecific Antibody Drugs Profile<\/b><\/p>\n Amivantamab: Janssen<\/b><\/p>\n Amivantamab is a fully human bispecific antibody that targets two well-established cancer-related proteins, EGFR and Met. In July 2012, Genmab partnered with Janssen Biotech, Inc. to develop bispecific antibodies utilizing Genmab\u2019s DuoBody technology platform. Both antibody libraries used in the creation of amivantamab were developed by Genmab, and the final antibody combination was selected jointly by Genmab and Janssen. Janssen subsequently led the development process. In 2021, the U.S. FDA approved amivantamab-vmjw (marketed as RYBREVANT) for treating adults with locally advanced or metastatic non-small cell lung cancer harboring EGFR Exon 20 insertion mutations, following progression after platinum-based chemotherapy. This marked the first regulatory approval for a therapeutic developed using Genmab\u2019s proprietary DuoBody bispecific technology.<\/p>\n Blinatumomab: Amgen<\/b><\/p>\n Blinatumomab (AMG 103) is a bispecific T cell engager (BiTE\u00ae) antibody that harnesses the body\u2019s T cells to target and eliminate cells expressing CD19, a protein commonly found on B-cell derived leukemias and lymphomas. This engineered antibody binds to two distinct targets at once, bringing T cells into close proximity with cancer cells to promote their destruction. As the first BiTE antibody developed, Blinatumomab has received orphan drug status from the U.S. FDA for treating acute lymphoblastic leukemia, chronic lymphocytic leukemia, hairy cell leukemia, prolymphocytic leukemia, and indolent B-cell lymphoma. The European Medicines Agency has granted similar designation for ALL, CLL, mantle cell leukemia, and indolent B-cell lymphoma. It is approved for use in treating Precursor B-cell lymphoblastic leukemia-lymphoma and is also under investigation for indications including Non-Hodgkin\u2019s lymphoma and diffuse large B-cell lymphoma.<\/p>\n Find out more about the FDA-approved bispecific antibody list @ Bispecific Antibody Drugs<\/b><\/a><\/p>\n Bispecific Antibody Market Dynamics<\/b><\/a><\/p>\n The bispecific antibody market is experiencing dynamic growth, driven by advances in antibody engineering and increasing demand for more effective, targeted cancer therapies<\/b>. Unlike traditional monoclonal antibodies, bispecific antibodies are designed to simultaneously bind two different antigens or epitopes, enabling novel mechanisms of action such as T-cell redirection, dual signaling pathway inhibition, or tumor microenvironment modulation. This unique functionality is particularly valuable in oncology, where BsAbs can bridge T-cells with tumor cells, leading to more potent and specific immune responses<\/b>.<\/p>\n The market dynamics are further shaped by a surge in R&D investment and a growing pipeline<\/b> of bispecific candidates. Leading companies, including Roche, Regeneron, Genmab, and Zymeworks, <\/b>among others, are actively developing platforms that improve BsAb stability, manufacturability, and half-life. Emerging formats such as knob-into-hole, CrossMab, and DuoBody<\/b> are addressing previous limitations related to molecule size, immunogenicity, and production complexity, thereby accelerating the pace of development and regulatory approval.<\/p>\n Despite the scientific excitement, the bispecific antibody market faces several challenges. Manufacturing remains technically complex and cost-intensive<\/b>, particularly when producing asymmetric or multivalent molecules. Additionally, safety concerns<\/b> such as cytokine release syndrome (CRS), off-target effects, and immunogenicity continue to be significant barriers. As more bispecifics enter clinical trials, patient stratification and biomarker development<\/b> are becoming increasingly important to ensure therapeutic efficacy and minimize adverse events.<\/p>\n In summary, the bispecific antibody market is at a critical inflection point, with tremendous potential to transform therapeutic strategies across multiple disease areas. Scientific innovation, regulatory support, and strategic investment are aligning to drive both clinical and commercial success. However, the path forward will require continued advances in platform technology, manufacturing optimization, and risk mitigation to fully realize the promise of bispecific antibodies in the global therapeutics market.<\/p>\n To know more about bispecific antibodies, visit @ Bispecific Antibody Production<\/b><\/a><\/p>\n A snapshot of the pipeline bispecific antibodies mentioned in the report:<\/b><\/p>\n\n
![](\"https:\/\/ml.globenewswire.com\/Resource\/Download\/f1358218-5a42-4fce-bdfc-f31ed10fb92b\/bispecific-antibody-competitive-landscape.jpg\" "\\"Bispecific-Antibody-Competitive-Landscape.jpg\\"")
<\/p>\n
![\"\"](\"https:\/\/ml.globenewswire.com\/media\/NzNkMmI2MTEtNjU4Yy00Njc4LTk4ZGEtZDRjZDZlMTczZGYzLTEyMDQ5MzgtMjAyNS0wNy0wNy1lbg==\/tiny\/DelveInsight-Business-Research.png\")
\n <\/div>\n","protected":false},"excerpt":{"rendered":"